Mouse Anti-HIV-1 gp120 Recombinant Antibody (clone 0.5β) (CAT#: PABZ-061)

Recombinant Mouse Antibody (0. 5β) is capable of binding to HIV-1 gp120, expressed in mammalian cells. The affinity of 0. 5β for the V3 peptide P1053 (RKSIRIQRGPGRAFVTIG) was found to be comparable to its affinity for the intact glycoprotein.

Specific Inquiry Online Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Datasheet
  • MSDS
  • COA

Figure 1 Titration of the 0.5β Fv fragment with wild-type peptide monitored by fluorescence enhancement.

Figure 1 Titration of the 0.5β Fv fragment with wild-type peptide monitored by fluorescence enhancement.

The concentration of the 0.5β Fv fragment was 0.5 μM.

Faiman, G. A., Levy, R., Anglister, J., & Horovitz, A. (1996). Contribution of Arginine Residues in the RP135 Peptide Derived from the V3 Loop of gp120 to Its Interaction with the Fv Fragment of the 0.5 β HIV-1 Neutralizing Antibody. Journal of Biological Chemistry, 271(23), 13829-13833.

Figure 2 Neutralization of the HTLV-IIB and the Mutant P313-A Viruses by V3 Loop-Specific Antisera

Figure 2 Neutralization of the HTLV-IIB and the Mutant P313-A Viruses by V3 Loop-Specific Antisera

The neutralization titers represent the dilution of antisera which inhibited RT release from virus challenged cells by 90%. 9284 and 0.5β are monoclonal antibodies to the HTLVIIIB virus which have been shown to bind the V3 loop region with different specificity.

IVANOFF, L. A., LOONEY, D. J., McDANAL, C. H. A. R. L. E. N. E., MORRIS, J. F., WONG-STAAL, F. L. O. S. S. I. E., LANGLOIS, A. J., ... & MATTHEWS, T. J. (1991). Alteration of HIV-1 infectivity and neutralization by a single amino acid replacement in the V3 loop domain. AIDS research and human retroviruses, 7(7), 595-603.

Figure 3 Comparison of the cell fusion blocking activity of V3 loop-specific antisera on HIV-1 infected T cells.

Figure 3 Comparison of the cell fusion blocking activity of V3 loop-specific antisera on HIV-1 infected T cells.

CEM T cells chronically infected with either the HTLV-IIIB virus or the P313-A mutant virus were mixed with uninfected MOLT-4 T cells in the presence of various antisera (see legend in Table 1 for a description). After 24 h, multinucleated syncytia were enumerated. Open symbols, HTLV-IIIB virus; Closed symbols, mutant P313-A virus. (A) Comparative activity of three polyclonal antisera: anti-PB1 (open boxes, closed boxes) anti-RP135 (open triangles, closed triangles); and anti-P-A peptide (open circles, closed circles). Preimmune goat and guinea pig had no effect on syncytia number. (B) Relative activity of two monoclonal antibodies: 9284 (open circles, closed circles) and 0.5β(open boxes, closed boxes).

IVANOFF, L. A., LOONEY, D. J., McDANAL, C. H. A. R. L. E. N. E., MORRIS, J. F., WONG-STAAL, F. L. O. S. S. I. E., LANGLOIS, A. J., ... & MATTHEWS, T. J. (1991). Alteration of HIV-1 infectivity and neutralization by a single amino acid replacement in the V3 loop domain. AIDS research and human retroviruses, 7(7), 595-603.


Specifications

  • Host Species
  • Mouse
  • Type
  • Mouse IgG
  • Specificity
  • Tested positive against HIV-1 gp120
  • Species Reactivity
  • HIV-1
  • Clone
  • 0.5β
  • Applications
  • Neut Assay-Dependent

Product Property

  • Purity
  • >95% as determined by SDS-PAGE
  • Concentration
  • Please refer to the vial label for the specific concentration.
  • Buffer
  • PBS
  • Preservative
  • No preservatives
  • Storage
  • Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Applications

  • Application Notes
  • The antibody 0.5β has been reported in application of Neut. It's recommended that the optimal antibody concentration, dilution, incubition time etc. are best to be carefully titrated in specific assays.

Target

  • Alternative Names
  • ENV; gp160; envelope glycoprotein; Envelope surface glycoprotein gp160, precursor; hypothetical protein; Envelope surface glycoprotein gp120; Envelope transmembrane domain

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone 0.5β"

See other products for "HIV-1 gp120"

Recombinant Antibody

Chimeric Antibody

CAT Product Name Application Type
MRO-135LC Anti-HIV-1 gp120 Recombinant Antibody (CAG1-51-4) ELISA, WB, Neut Chimeric antibody (mouse/human)
MRO-135LC-S(P) Anti-HIV-1 gp120 Recombinant Antibody scFv Fragment (CAG1-51-4) ELISA, WB Chimeric antibody (mouse/human)
MRO-135LC-F(E) Anti-HIV-1 gp120 Recombinant Antibody Fab Fragment (CAG1-51-4) ELISA, WB Chimeric antibody (mouse/human)

Rabbit Monoclonal Antibody

CAT Product Name Application Type
MOR-4220 Rabbit Anti-HIV-1 gp120 Recombinant Antibody (clone SI299DS) WB, ELISA Rabbit IgG

Humanized Antibody

CAT Product Name Application Type
PABX-101-S(P) Human Anti-HIV-1 gp120 Recombinant Antibody (clone PG9); scFv Fragment WB, ELISA, FuncS Human scFv

Submit a review or a question
There are currently no Customer reviews or questions for PABZ-061. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

  • 0
  • 0
Cart
    Go to compare

    Go to compare